Dr. Paloma H Giangrande, an Expert in Nucleic Acid Therapeutics, Named CTO at Eleven Therapeutics
Eleven Therapeutics, a leading biotechnology company focused on developing innovative nucleic acid therapeutics, has recently announced the appointment of Dr. Paloma H Giangrande as their Chief Technology Officer (CTO). With her extensive expertise in the field of nucleic acid therapeutics, Dr. Giangrande is expected to play a crucial role in advancing the company’s research and development efforts.
Nucleic acid therapeutics have emerged as a promising approach for treating a wide range of diseases, including cancer, genetic disorders, and viral infections. These therapeutics utilize nucleic acids, such as DNA or RNA, to target specific genes or gene products involved in disease processes. By modulating gene expression or inhibiting the production of disease-causing proteins, nucleic acid therapeutics offer a highly targeted and potentially curative treatment option.
Dr. Giangrande brings a wealth of experience to her new role at Eleven Therapeutics. She holds a Ph.D. in Molecular Biology from the University of Buenos Aires and has conducted groundbreaking research in the field of nucleic acid therapeutics throughout her career. Her work has focused on developing novel delivery systems for nucleic acids, improving their stability and efficacy, and exploring their potential applications in various disease settings.
Prior to joining Eleven Therapeutics, Dr. Giangrande served as an Associate Professor at the University of Iowa, where she led a research laboratory dedicated to studying nucleic acid-based therapies. Her work has been published in numerous high-impact scientific journals and has garnered recognition from the scientific community.
As CTO of Eleven Therapeutics, Dr. Giangrande will be responsible for overseeing the company’s research and development activities related to nucleic acid therapeutics. She will lead a team of scientists and researchers in designing and optimizing novel nucleic acid-based therapies, with the ultimate goal of advancing these therapies into clinical trials and ultimately to market.
Dr. Giangrande’s appointment comes at a critical time for Eleven Therapeutics, as the company is actively working on several promising nucleic acid therapeutics programs. With her expertise and leadership, the company aims to accelerate the development of these therapies and bring them closer to patients in need.
In addition to her role at Eleven Therapeutics, Dr. Giangrande is also an active member of various scientific organizations and serves on the editorial boards of several scientific journals. She is committed to advancing the field of nucleic acid therapeutics and has been involved in mentoring and training the next generation of scientists in this field.
The appointment of Dr. Paloma H Giangrande as CTO at Eleven Therapeutics highlights the company’s commitment to advancing nucleic acid therapeutics and underscores the importance of this field in modern medicine. With her expertise and leadership, Dr. Giangrande is poised to make significant contributions to the development of innovative therapies that have the potential to revolutionize the treatment of various diseases.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/dr-paloma-h-giangrande-appointed-cto-at-eleven-therapeutics-a-prominent-figure-in-nucleic-acid-therapeutics-for-over-a-decade-medical-device-news-magazine/
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...